Onabotulinumtoxin-A for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Mar 2022: Trial started, NCT05284019
  2. 17 Mar 2022: Trial registered, NCT05284019
  3. 14 Apr 2023: Trial terminated, NCT05284019
  4. 29 May 2024: Trial results posted, NCT05284019

The trials

NCT05284019: Real World Effectiveness of Eptinezumab in Participants With Migraine

State
Stopped early
Phase
Phase 4
People
32 taking part
Started
4 Mar 2022
Primary completion
17 Feb 2023
Arms
Onabotulinumtoxin-A
Results
Posted on the registry
  1. 4 Mar 2022: Trial started
  2. 17 Mar 2022: Trial registered
  3. 14 Apr 2023: Trial terminated
  4. 29 May 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.